Sanofi Makes $202M Investment in Vax Facility

Oct 16, 2017

Sanofi, confident in the growth of its influenza vaccines, has committed to spending $202 million to build a new manufacturing facility at its Val-de-Reuil site in north-western France.

The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to expand its supply of influenza vaccine, VaxigripTetra, to up to 70 countries in six continents. Sanofi Pasteur remains the sole influenza vaccine producer in the country.

The new facility, which will be the only site of its kind in France, will be completed by 2021 and should begin producing vaccines by 2022.

Read the press release

 

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments